221 related articles for article (PubMed ID: 37088789)
1. Clinical risk management of breast, ovarian, pancreatic, and prostatic cancers for BRCA1/2 variant carriers in Japan.
Ueki A; Yoshida R; Kosaka T; Matsubayashi H
J Hum Genet; 2023 Aug; 68(8):517-526. PubMed ID: 37088789
[TBL] [Abstract][Full Text] [Related]
2. Bilateral prophylactic mastectomy in BRCA mutation carriers: what surgeons need to know.
Franceschini G; Di Leone A; Terribile D; Sanchez MA; Masetti R
Ann Ital Chir; 2019; 90():1-2. PubMed ID: 30872561
[TBL] [Abstract][Full Text] [Related]
3. Different Patterns of Risk Reducing Decisions in Affected or Unaffected BRCA Pathogenic Variant Carriers.
Lee EG; Kang HJ; Lim MC; Park B; Park SJ; Jung SY; Lee S; Kang HS; Park SY; Park B; Joo J; Han JH; Kong SY; Lee ES
Cancer Res Treat; 2019 Jan; 51(1):280-288. PubMed ID: 29747489
[TBL] [Abstract][Full Text] [Related]
4. Experience of risk-reducing salpingo-oophorectomy for a BRCA1 mutation carrier and establishment of a system performing a preventive surgery for hereditary breast and ovarian cancer syndrome in Japan: our challenges for the future.
Hirasawa A; Masuda K; Akahane T; Tsuruta T; Banno K; Makita K; Susumu N; Jinno H; Kitagawa Y; Sugano K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2013 May; 43(5):515-9. PubMed ID: 23487443
[TBL] [Abstract][Full Text] [Related]
5. Retrospective evaluation of risk-reducing salpingo-oophorectomy for BRCA1/2 pathogenic variant carriers among a cohort study in a single institution.
Kobayashi Y; Hirasawa A; Chiyoda T; Ueki A; Masuda K; Misu K; Kawaida M; Hayashi S; Kataoka F; Banno K; Kosaki K; Aoki D
Jpn J Clin Oncol; 2021 Feb; 51(2):213-217. PubMed ID: 33037428
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of surveillance and prevention strategies in BRCA1/2 mutation carriers.
Yamauchi H; Nakagawa C; Kobayashi M; Kobayashi Y; Mano T; Nakamura S; Arai M
Breast Cancer; 2018 Mar; 25(2):141-150. PubMed ID: 29019095
[TBL] [Abstract][Full Text] [Related]
7. Differences in Ovarian and Other Cancers Risks by Population and
Sekine M; Nishino K; Enomoto T
Genes (Basel); 2021 Jul; 12(7):. PubMed ID: 34356066
[TBL] [Abstract][Full Text] [Related]
8. Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.
Uyei A; Peterson SK; Erlichman J; Broglio K; Yekell S; Schmeler K; Lu K; Meric-Bernstam F; Amos C; Strong L; Arun B
Cancer; 2006 Dec; 107(12):2745-51. PubMed ID: 17109443
[TBL] [Abstract][Full Text] [Related]
9. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
10. Management of breast cancer risk in BRCA1/2 mutation carriers who are unaffected with cancer.
Collins JM; Isaacs C
Breast J; 2020 Aug; 26(8):1520-1527. PubMed ID: 32652823
[TBL] [Abstract][Full Text] [Related]
11. Impact of the coverage of risk-reducing salpingo-oophorectomy by the national insurance system for women with BRCA pathogenic variants in Japan.
Nomura H; Abe A; Fusegi A; Yoshimitsu T; Misaka S; Murakami A; Matsumoto T; Tsumura S; Kanno M; Aoki Y; Netsu S; Omi M; Tanigawa T; Okamoto S; Omatsu K; Yunokawa M; Kanao H; Habano E; Arakawa H; Kaneko K; Ueki A; Haruyama Y; Inari H; Ueno T
Sci Rep; 2023 Jan; 13(1):1018. PubMed ID: 36658289
[TBL] [Abstract][Full Text] [Related]
12. [Current clinical issues and recent trends in hereditary breast and ovarian cancer in Japan-genetic testing for HBOC and risk-reducing surgery].
Arai M; Iwase T; Takazawa Y; Takeshima N
Gan To Kagaku Ryoho; 2014 Nov; 41(11):1333-9. PubMed ID: 25434434
[TBL] [Abstract][Full Text] [Related]
13. A Microsimulation Model for Evaluating the Effectiveness of Cancer Risk Management for BRCA Pathogenic Variant Carriers: miBRovaCAre.
Petelin L; Hossack L; Mitchell G; Liew D; Trainer AH; James PA
Value Health; 2019 Aug; 22(8):854-862. PubMed ID: 31426925
[TBL] [Abstract][Full Text] [Related]
14. Trends and timing of risk-reducing mastectomy uptake in unaffected BRCA1 and BRCA2 carriers in Slovenia.
Ložar T; Žgajnar J; Perhavec A; Blatnik A; Novaković S; Krajc M
Eur J Surg Oncol; 2021 Aug; 47(8):1900-1906. PubMed ID: 33812767
[TBL] [Abstract][Full Text] [Related]
15. Correlation between the risk of ovarian cancer and BRCA recurrent pathogenic variants in Japan.
Sekine M; Enomoto T; Arai M; Yokoyama S; Nomura H; Nishino K; Ikeuchi T; Kuriyama Y; Nakamura S;
J Hum Genet; 2022 May; 67(5):267-272. PubMed ID: 34983974
[TBL] [Abstract][Full Text] [Related]
16. Management updates for women with a BRCA1 or BRCA2 mutation.
Nusbaum R; Isaacs C
Mol Diagn Ther; 2007; 11(3):133-44. PubMed ID: 17570734
[TBL] [Abstract][Full Text] [Related]
17. Biologic behavior of resected BRCA-mutated pancreatic cancer: Comparison with sporadic pancreatic cancer and other BRCA-related cancers.
Kim SH; Hwang HK; Lee WJ; Kang CM
Pancreatology; 2021 Apr; 21(3):544-549. PubMed ID: 33612442
[TBL] [Abstract][Full Text] [Related]
18. Prevalence of BRCA1 and BRCA2 large genomic rearrangements in Tunisian high risk breast/ovarian cancer families: Implications for genetic testing.
Riahi A; Chabouni-Bouhamed H; Kharrat M
Cancer Genet; 2017 Jan; 210():22-27. PubMed ID: 28212807
[TBL] [Abstract][Full Text] [Related]
19.
Lee A; Moon BI; Kim TH
Ann Lab Med; 2020 Mar; 40(2):114-121. PubMed ID: 31650727
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
